Holen Sie sich die Stockscreener-App
67.00
0.28%
-0.00
Schlusskurs vom Vortag:
$67.00
Offen:
$67.52
24-Stunden-Volumen:
177.22K
Relative Volume:
0.37
Marktkapitalisierung:
$2.56B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-212.18M
KGV:
-11.19
EPS:
-5.9897
Netto-Cashflow:
$-181.33M
1W Leistung:
-7.17%
1M Leistung:
-2.12%
6M Leistung:
-27.57%
1J Leistung:
+33.57%
1-Tages-Spanne:
$65.21
$67.52
1-Wochen-Bereich:
$65.21
$72.83
52-Wochen-Spanne:
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Firmenname
Disc Medicine Inc
Sektor
Branche
Telefon
(617) 674-9274
Adresse
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
67.00 | 2.56B | 0 | -212.18M | -181.33M | -5.9897 |
VRTX
Vertex Pharmaceuticals Inc
|
445.51 | 113.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
621.23 | 66.62B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.39 | 55.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.00 | 40.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.50 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Stifel | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-11 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-02-27 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-01 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-17 | Eingeleitet | Raymond James | Outperform |
| 2023-04-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Eingeleitet | Stifel | Buy |
| 2023-04-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-03-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Disc Medicine Inc Aktie (IRON) Neueste Nachrichten
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Caledonian Record
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Fierce Biotech Layoff Tracker 2026: Fulcrum cuts 85% of staff; Novartis trims research team - Fierce Biotech
Liquidity Mapping Around (IRON) Price Events - Stock Traders Daily
Diamond Blackfan Anemia Market Unlocking New Revenue - openPR.com
Medpace Deadline: MEDP Investors with Losses in Excess of $100K Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit - PR Newswire
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - PR Newswire
BRTX: Advancing late-stage cell therapies for spine, metabolic, and aesthetic markets with strong IP - TradingView
IRON: Bitopertin advances toward pivotal data and regulatory milestones, targeting broad anemia indications - TradingView
Program provides early access to experimental EPP treatment - Porphyria News
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $111 - Moomoo
A Quick Look at Today's Ratings for Disc Medicine(IRON.US), With a Forecast Between $100 to $118 - Moomoo
Stifel reiterates Disc Medicine stock rating on anemia trial data By Investing.com - Investing.com Australia
Stifel reiterates Disc Medicine stock rating on anemia trial data - Investing.com
Disc Medicine (IRON) Reports Promising Results from RALLY-MF Pha - GuruFocus
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Experimental anemia drug cuts transfusions in myelofibrosis trial - Stock Titan
How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients - Yahoo Finance
Disc Medicine Launches Expanded Access Program for Bitopertin for Epp Patients - marketscreener.com
Disc Medicine launches expanded access program for bitopertin By Investing.com - Investing.com South Africa
Disc Medicine launches expanded access program for bitopertin - Investing.com
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients - The Manila Times
Disc program offers EPP patients bitopertin before FDA decision - Stock Titan
IRON Technical Analysis & Stock Price Forecast - Intellectia AI
STLA Deadline: STLA Investors with Losses in Excess of $100K Have Opportunity to Lead Stellantis N.V. Securities Fraud Lawsuit - PR Newswire
IRON Should I Buy - Intellectia AI
Seven Grand Managers LLC Buys Shares of 35,000 Disc Medicine, Inc. $IRON - MarketBeat
Press releases provided by CNW - Techaeris
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data - inkl
Disc Medicine eyes mid-2026 bitopertin approval as EPP trial demand surges - MSN
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges - MarketBeat
Class action lawsuit launched over Disc Medicine's FDA drug rejection causing 22% stock drop - Pluang
Why (IRON) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Disc Medicine faces class action after FDA rejects drug application, stock drops 22%. - Pluang
IRON News | DISC MEDICINE INC (NASDAQ:IRON) - ChartMill
Eagle Health Investments LP Purchases Shares of 27,100 Disc Medicine, Inc. $IRON - MarketBeat
IRON: APOLLO study enrollment exceeded targets, signaling high demand and unmet need for EPP therapies - TradingView
DNB Asset Management AS Raises Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
First Light Asset Management, LLC's Disc Medicine Inc(IRON) Holding History - GuruFocus
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inqui - GuruFocus
Disc Medicine faces class action after FDA rejects drug application, stock drops 22% - Pluang
UBS Group AG Reduces Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative? - simplywall.st
Disc Medicine, Inc.Common Stock (NQ: IRON - FinancialContent
IRON Maintained by Morgan Stanley -- Price Target Raised to $80. - GuruFocus
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON) - The Globe and Mail
Morgan Stanley Raises Price Target on Disc Medicine to $80 From $75, Keeps Overweight Rating - marketscreener.com
Morgan Stanley Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $80 - Moomoo
Understanding Momentum Shifts in (IRON) - Stock Traders Daily
Finanzdaten der Disc Medicine Inc-Aktie (IRON)
Umsatz
Nettogewinn
Free Cashflow
ENV
Disc Medicine Inc-Aktie (IRON) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Franchi Jean M. | Chief Financial Officer |
Apr 14 '26 |
Sale |
69.24 |
6,257 |
433,234 |
64,333 |
| Franchi Jean M. | Chief Financial Officer |
Apr 13 '26 |
Sale |
69.00 |
400 |
27,600 |
70,590 |
0.16%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):